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Functional dyspepsia is a highly prevalent disease worldwi-
de. Its symptoms are manifested as pain (burning or not) in 
the upper abdomen and early satiety, postprandial fullness, 
bloating, nausea and belching. For its study and treatment, 
it is divided into 2 syndromes: epigastric pain, which is meal 
unrelated, and postprandial distress, which as the name su-
ggests, are meal related symptoms. these 2 syndromes fre-
quently overlap.1
the term functional dyspepsia implies a patient with upper 
digestive symptoms whose endoscopy reveals a normal sto-
mach and duodenum or with minimum changes, the Rome III 
criteria diagnoses this disease; nevertheless, recent studies 
suggest the need to modify the temporality criteria.
categorizing patients into 2 syndromes has therapeutic 
implications, which are based on pathophysiological mecha-
nisms, considering that patients with epigastric pain may 
have hypersensitivity or a Helicobacter pylori (H. pylori) in-
fection, while patients with postprandial distress may suffer 
fundic-relaxation or gastric emptying issues.
Within the therapeutic approach of functional dyspepsia, 
there are important pharmacological and non-pharmacolo-
gical measures, including: 
Non-pharmacological measures
a. Diet
We suggest avoiding foods such as: soft drinks, coffee, tea, 
chocolate, mint, peppermint, garlic, onion, tomato, pepper, 
gum, spices and citrus, as well as excessive amounts of fruit 
and vegetables, especially when symptoms suggest pro-
blems with gastric emptying. once the patient improves, 
these foods should be re-introduced in an orderly fashion to 
test tolerance. 
b. Upper gastrointestinal (GI) endoscopy
It is necessary for a functional dyspepsia diagnosis, yet not 
for all patients. Indications include: recent onset dyspepsia 
in people older than 50, weight loss, nocturnal symptoms, 
and evidence of anemia or digestive hemorrhage. patients 
with dyspepsia beneit from the endoscopy, because this has 
proved to reduce anxiety rates by ruling out cancer or a 
peptic ulcer.
c. avoid alcohol, tobacco and non-steroidal 
anti-inlammatory drug (nsaIDs)
these are unarguably dyspepsia generators and are associa-
ted with peptic ulcers. We suggest avoiding them due to 
their GI toxicity.
d. Psychoeducation and psychotherapy
prevalence of depression and especially of anxiety is high in 
patients with dyspepsia. It is important to detect such di-
seases and treat them, since these may increase the per-
ception of symptoms. In our experience, symptoms such as 
nausea are associated independently with anxiety and the 
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degree of anxiety is positively correlated with the intensity 
of the symptoms.2 
We strongly recommend the use of tools like the in hospi-
tal anxiety and Depression scale survey (validated in Me- 
xico) as well as the Rome psychosocial alarm survey for 
anxiety and depression detection in patients with dyspep-
sia.
Pharmacological measures
Finding pharmacological measures that function better than 
the placebo is deinitely a hard task in functional disorders, 
because placebos have a very high effect to control dyspep-
sia, from 30% up to 70%. In case of functional dyspepsia we 
must remember that we are dealing with 2 diseases instead 
of just one (epigastric pain and postprandial discomfort), 
which may coexist. thus, we must examine patients for the 
presence of each and every one of the symptoms, which will 
tell us the pathophysiological aspect involved, and enable 
us to treat the patient based or their symptoms. Most of 
the published clinical trials about functional dyspepsia 
treatment evaluate for both types of dyspepsia; hence, the 
results must be carefully interpreted. the eficacy of diffe-
rent pharmacological treatments for functional dyspepsia is 
variable (table 1).
Available pharmacological treatments for 
dyspepsia:
•	 H. pylori eradication treatment: one of the 
patient’s biggest fears about dyspepsia is having H. 
pylori, the patients show a major concern caused 
by a microorganism, which may have been in their 
stomachs for a long time already. Eradication 
treatment has an effectiveness measured as a 
number needed to treat (nnt) of 14, which in spe-
cialty care is not too effective. nevertheless, a 
recent clinical trial shows that it is a good strategy 
in primary care medicine as well as in places of 
high prevalence like our county. some patients be-
neited by this treatment are those who manifest 
pain. 
•	 Anti-secretory drugs: Both type-2 anti-histaminer-
gic pharmaceuticals (i. e. ranitidine) as well as 
proton pump inhibitors are medications of modera-
te eficacy with an nnt of 8 and 9, respectively. 
patients who may be beneited by the use of these 
medications are those with burning pain, overlap-
ping with gastroesophageal relux (frequent in our 
population, up to 50%). however, it is important to 
know that the patients who beneit the least are 
those with postprandial distress, considering that 
gastric emptying studies have proven that proton 
pump inhibitor (ppI) reduces solids rate and this 
could worsen the symptoms. 
•	 Prokinetics: these are useful medications in the 
treatment of postprandial distress syndrome; 
however researchers in Us forget them because its 
therapeutic dosage approaches the level of dosage 
which causes adverse effects. nevertheless, when 
these are used wisely, it gives dyspepsia patients a 
major beneit with an nnt of 5. It is important to 
highlight that there is a considerable amount of 
prokinetics available in Mexico, but we must chose 
the one that, in addition to being effective, has an 
acceptable safety proile.
•	 Antidepressants: highly effective medications in 
the treatment of dyspepsia since they work as vis-
ceral analgesics. It is important to highlight that 
the use of these medications is for pain manage-
ment. however, we must evaluate the presence of 
subjacent anxiety or depression for their treatment.3 
Selective serotonin receptor inhibitors have only 
proved to have a positive effect over quality of life 
but not in pain. a recent study showed preliminary 
results demonstrating that amitriptyline is better 
than a placebo for dyspepsia management, yet not 
escitalopram. tricyclic antidepressants are modu-
lators of the perception of pain; their prescription 
in the treatment of dyspepsia should follow the 
concept of “low and slow”: effective dosages in 
dyspepsia tend to be lower than those for depres-
sion and their therapeutic effects tend to be noti-
ced sooner than in depression. this treatment’s 
effectiveness is proven with an nnt of 2. It is im-
portant to consider that before the prescription of 
a tricyclic, organic diseases must have been ruled 
out because these medications have been demons-
trated to be effective for pain management in ge-
neral and it could be masking other causes. We 
must emphasize and consider that if we want to 
treat anxiety or depression there are other medi-
cations with better results, thus my suggestion 
would be to refer to a specialist for its manage-
ment and maintain the tricyclic’s minimum effecti-
ve dosage. Recent studies have demonstrated that 
amitriptyline can manage pain, as well as nausea4 
(regardless of the fact that one of its effects is to 
delay gastric emptying) and even can be found in 
the american college of Gastroenterology gastro-
paresis management guide because of its effect 
over this problematic symptom.
Regarding dyspepsia treatment duration the suggestion is 
3 months; however, the use of tricyclic as an option can be 
considered up to 6 months (there is not a well-established 
time). 
Table 1 Eficacy of pharmacological treatments for 
functional dyspepsia.
treatment Studies Points nnt (95% cI)
tricyclics 4 167 2 (1.5-5)
prokinetics 17 4,495 5 (3-11)
anti-h2 11 2,164 8 (5-24)
PPI 13 5,660 9 (6-19)
H. pylori  
eradication
21 4,331 14 (10-20)
nnt: needed to treat; cI: conidence interval; ppI: proton pump 
inhibitor; H. pylori: Helicobacter pylori.
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Functional dyspepsia is more complex than we think and 
therapeutic development seems to be stagnant for some 
years now. Management guidelines are different based on 
prokinetic availability; always consider H. pylori eradication 
as a irst choice. they suggest subdividing the patient into 2 
groups (epigastric pain or postprandial distress); however, it 
is very frequent that the patient suffers both (up to 50%). 
therefore my recommendation is to consider the fact that 
symptoms are the key to establishing a treatment plan, be-
cause they can explain whether the patient is hypersensiti-
ve and requires a tricyclic, if the patient has gastric 
relaxation or emptying issues where a prokinetic would be 
ideal, or if acid is casual and an anti-secretor would be the 
best option. Even though we must consider that the best 
option is probably the combination of 2 or more medications 
based on the symptoms.
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